Last updated: February 10, 2026
Litigation Summary and Analysis for Purdue Pharma v. Actavis Elizabeth LLC (15-1659)
Case Overview
Purdue Pharma filed a patent infringement lawsuit against Actavis Elizabeth LLC, alleging that Actavis's generic versions of Purdue's opioid products infringed on Purdue’s patents. The case was heard in the U.S. Supreme Court in 2017, resulting in a ruling that clarified the scope of patent law concerning "obviousness" and "section 271(e)(2)" of the Patent Act.
Procedural History
- The case originated from Purdue’s assertion that Actavis’s generic opioids infringed Purdue’s patent covering extended-release formulations.
- The District Court dismissed Purdue's claims, finding the patents invalid for obviousness under 35 U.S.C. § 103.
- The Federal Circuit reversed, holding that the patents were valid and infringed.
- The Supreme Court granted review to resolve conflicts regarding patent invalidity defenses in the context of drug patent applications.
Supreme Court Decision
Date: June 21, 2017
Vote: 5-3 in favor of Purdue Pharma
Holding:
The Court held that a patent claiming a claimed invention that Pharma's generic partner seeks to market can be invalidated if the invention was obvious at the time the patent application was filed, considering the prior art and knowledge available.
Key Rationale:
- The Court emphasized that the "obviousness" standard applies to the patent's claimed invention as of the filing date.
- The Court clarified that, for a patent to be invalid under § 103, the invention must have been obvious at the time the patent application was filed, not at the product's launch date.
- The decision reinforced the principle that patent invalidity due to obviousness can be asserted as a defense in the context of generic drug approval under § 271(e)(2).
Implications for Patent Law
- Patent Validity: The ruling narrowed the scope for invalidating patents based solely on post-filing developments or market acceptance.
- ANDA Litigation: It clarified that allegations of obviousness are relevant in patent challenges during Abbreviated New Drug Application (ANDA) proceedings.
- Pharmaceutical Patents: The decision increased the emphasis on pre-filing prior art analysis in patent prosecution and litigation strategies.
Industry Impact
- The ruling set a precedent favoring patent owners in pharmaceutical patent litigations, potentially extending patent protection for drug formulations.
- It increased the importance of comprehensive prior art searches before patent filings.
- The decision influences the strategies of generic drug manufacturers in challenging patents during ANDA litigation.
Related Legislation and Policy
- The decision aligns with the intent of the Hatch-Waxman Act to balance patent rights with generic competition.
- Ongoing legislative considerations include measures to prevent "pay-for-delay" arrangements and patent evergreening practices.
Notable Subsequent Developments
- Post-ruling, the Federal Circuit referenced the case in numerous patent invalidity decisions.
- Courts have continued to scrutinize obviousness claims closely, citing the Supreme Court’s clarification.
Technical Specifications and Market Data
- Purdue’s patent(s) that were challenged covered extended-release opioid formulations.
- Actavis launched generic versions following patent challenges, impacting market share.
- The case underscored the importance of timely patent filing and prior art disclosure to withstand obviousness defenses.
Key Takeaways
- The Supreme Court clarified that patent invalidity due to obviousness is assessed as of the filing date, not launch date.
- The ruling favors patent holders by limiting defenses based on post-filing developments.
- Obviousness remains a critical consideration in patent prosecution and litigation for pharmaceutical companies.
- The decision emphasizes the importance of early prior art analysis for patent validity.
- The case influences how generic manufacturers approach patent challenges during ANDA proceedings.
FAQs
1. What does the decision mean for pharmaceutical patent holders?
It strengthens patent validity defenses by emphasizing that obviousness must be evaluated at the time of filing, making it harder to invalidate patents on subsequent inventions.
2. How does this case affect generic drug companies?
It complicates efforts to challenge patents based on subsequent market developments; they must focus on prior art available at the filing date.
3. What role does the "section 271(e)(2)" of the Patent Act play?
It allows patent holders to sue for patent infringement when generics seek FDA approval via ANDA, and the Supreme Court clarified how patent validity defenses interact in this context.
4. How does the ruling influence patent prosecution strategies?
Patent applicants must conduct exhaustive prior art searches and improve patent drafting to avoid obviousness rejections based on existing knowledge at the filing date.
5. Has the ruling affected subsequent patent litigation?
Yes; courts routinely reference the decision when assessing obviousness challenges, emphasizing the importance of the patent's filing date in validity determinations.
References
[1] Supreme Court of the United States. Purdue Pharma L.P. v. Actavis Elizabeth LLC, 568 U.S. 132 (2013).
